Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rizwan Romee, M.D.

Profile Picture

2018 - 2019
Dunkin Donuts Breakthrough Grant
2015 - 2018
ASH Scholar Award (faculty)
2015 - 2018
ASCO Career Development Award (faculty)

As a translational physician-scientist my long-term goals are to translate novel aspects of immunology to improve treatments for patients with advanced malignancies. The primary research focus of my lab is gene manipulation of the human NK cells aimed at enhancing anti-tumor function and modulating tumor micro-environment. We are also working on developing novel ways to deliver potent cytokines to the tumor microenvironment and investigating ways to further enhance activity and targeting capabilities of memory-like NK cells.

We described human memory-like NK cells with enhanced anti-tumor activity and in a first in human clinical trial demonstrated safety and promising activity of these cells in relapsed / refractory AML patients. In clinic we are currently testing these memory-like NK cells in combination with novel immunemodulatory agents in patients with advanced malignancies.

I also lead our haploidentical transplant program at Dana Farber Cancer Institute and we are working to potentially use haploidentical donor transplantation as a platform to incorporate NK cell-based immunotherapy approaches for patients with high risk hematologic malignancies undergoing transplantation.

Available: 01/02/23, Expires: 01/01/25

We are using CRISPR based approaches to edit human NK cells to enhance their anti-tumor function and to overcome otherwise harsh tumor microenvironment. This project involves both genome wide screens and targeted gene knockouts. The student will learn the basics of immune cell gene editing including generation of CAR NK cells. Student is will work closely with a post doc and or a graduate student in the lab and help with designing vectors, RNA guides, transduction of NK cells, and assessing NK cell function using flow based assays.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. MMRF Innovations in Clinical Accelerator Program (Rizwan Romee) Nov 1, 2020 - Jan 1, 2023
    Multiple Myeloma Research Foundation (MMRF)
    Memory-like NK Cell Immunotherapy Plus CD38 ARM in MRD+ Multiple Myeloma and High Risk Smoldering Myeloma
    Role: Principal Investigator
  2. LLS Scholar Award (Rizwan Romee) Jul 1, 2020 - Jun 30, 2025
    Leukemia and Lymphoma Society
    Cytokine Induced Memory-Like NK Cell Immunotherapy to Target Post Transplant Relapse
    Role Description: The aim of this project is to target post transplant relapse by novel memory-like NK cells which have enhanced anti-tumor activity without causing graft versus host disease (GVHD).
    Role: Principal Investigator
  3. (Rizwan Romee) Jan 30, 2020 - Dec 31, 2022
    Gateway for Cancer Research
    Harnessing Innate Immunity in Solid Tumors: CTLA-4 Inhibition in Combination with Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck Cancer
    Role Description: We are assessing safety and potential efficacy of memory-like NK cells in patients with advanced head and neck cancer in combination with CTLA-4 blockade (aimed at intra-tumoral Treg depletion) and IL-15 super-agonist, N-803.
    Role: PI
  4. BARR Award (Rizwan Romee) Jan 1, 2020 - Dec 31, 2021
    Claudia Adams Barr Program
    Engineering Memory-Like NK Cells with a Novel CAR Construct Targeting a Neo-Epitope Derived from Intracellular Mutated Nucleophosmin-1 (NPM-1c) in Acute Myeloid Leukemia
    Role Description: This supports our research efforts aimed at genetic manipulation of the memory-like NK cells to enhance their ability to target and kill myeloid blasts.
    Role: Principal Investigator
  5. R21CA245413 (Rizwan Romee) Jan 1, 2020 - Dec 31, 2021
    Memory-like NK cells for enhanced immunotherapy of post transplant relapse in patients with myeloid malignancies
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Romee's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (333)
Co-Authors (80)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.